===============================================================================
                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

                                   (Mark One)
[ X ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                For the quarterly period ended January 31, 2004.

Transition Report Pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

             For the transition period from            to
                                            ----------    ----------
                         Commission file number: 0-32801

                                  TISSERA, INC.
        (Exact Name of Small Business Issuer as Specified in Its Charter)

                                BERT Logic, Inc.
                           (Former Name of Registrant)

               WASHINGTON                                       91-2034750
     (State or other jurisdiction of                         (I.R.S. Employer
     incorporation of organization)                         Identification No.)

    17 HATA'ASIA STREET, OR YEHUDA                             60212  ISRAEL
(Address of principal executive offices)                        (Zip Code)

            Issuer's telephone number: +972-542-544-344/(214)668-1897


              (Former Name, Former Address and Former Fiscal Year,
                         If Changed Since Last Report)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
                                                                   ---

As of March 15, 2004, the registrant had 22,380,740 shares of common stock
outstanding.

Transitional Small Business Disclosure Format (Check one): Yes      No  X
                                                               --      ---

===============================================================================

<PAGE>

TISSERA, INC.

INDEX


<TABLE>
<CAPTION>
PART I.  FINANCIAL INFORMATION                                               PAGE NUMBER
------------------------------                                               -----------

<S>                                                                          <C>
Item 1.  Financial statements
                  (unaudited)

         Consolidated Balance Sheets                                               3

         Consolidated Statements of Operations                                     4

                  Consolidated Statements of Changes in Stockholders'
                  Equity (Deficiency)                                              5

         Consolidated Statements of Cash Flows                                     6

                  Notes to Financial Statements                                 7-13

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                                      13

Item 3.   Controls and Procedures                                                 16

PART II.  OTHER INFORMATION                                                       17
---------------------------

Item 1. Legal Proceedings                                                         17

Item 2.  Change in Securities                                                     17

Item 3.  Defaults Upon Senior Securities                                          17

Item 4.  Submission of Matters to Vote of Security Holders                        17

Item 5.  Other Information                                                        17

Item 6.  Exhibits and Reports on Form 8-K                                         17

SIGNATURES                                                                        18
</TABLE>



<PAGE>



                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY
CONSOLIDATED BALANCE SHEETS
--------------------------------------------------------------------------------
IN U.S. DOLLARS

<TABLE>
<CAPTION>
                                                                        JANUARY 31,     JULY 31,
                                                                           2004            2003
                                                                        -----------    -----------
                                                                         UNAUDITED       AUDITED
                                                                        -----------    -----------
<S>                                                                         <C>         <C>
    ASSETS

CURRENT ASSETS:
  Cash                                                                      600,655             --
  Prepaid expenses                                                          190,229             --
                                                                        -----------    -----------

Total current assets                                                        790,884             --
                                                                        -----------    -----------

ASSETS ATTRIBUTED TO DISCONTIUNUED OPERATIONS                                    --          7,853
                                                                        -----------    -----------

Total assets                                                                790,884          7,853
                                                                        ===========    ===========

    LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)

CURRENT LIABILITIES
  Related parties - shareholders                                              1,023             --
  Accounts payable                                                           40,844             --
  Accrued expenses                                                          123,006             --
                                                                        -----------    -----------
                                                                            164,873             --
                                                                        -----------    -----------

ACCRUED SEVERANCE PAY                                                         4,640             --
                                                                        -----------    -----------
LIABILITIES ATTRIBUTED TO DISCONTINUED OPERATIONS                             2,500         17,677
                                                                        -----------    -----------
Total liabilities                                                           172,013         17,677
                                                                        -----------    -----------

SHAREHOLDERS' EQUITY (DEFICIENCY):
  Common shares of $ 0.0001 par value each -
    Authorized: 100,000,000 shares as of July 31, 2003 and January 1,
      2004; Issued and outstanding: 18,036,000 shares as of July 31,
      2003 and January 31, 2004                                               1,804          1,804
    Preferred shares of $ 0.0001 par value each -
    Authorized: 20,000,000 shares as of July 31, 2003 and January 1,
      2004; Issued and outstanding: 0 shares as of July 31,2003 and
      January 31, 2004                                                           --             --
  Additional paid-in capital                                              9,938,865         93,196
  Receipts on account of shares                                           1,801,470             --
  Accumulated deficit                                                   (11,123,268)      (104,824)
                                                                        -----------    -----------

Total shareholders' equity (deficiency)                                     618,871         (9,824)
                                                                        -----------    -----------

Total liabilities and shareholders equity (deficiency)                      790,884          7,853
                                                                        ===========    ===========
</TABLE>


The  accompanying  notes  are an  integral  part of the  consolidated  financial
statements.

                                       3
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY
CONSOLIDATED STATEMENT OF OPERATIONS
--------------------------------------------------------------------------------
IN U.S. DOLLARS



<TABLE>
<CAPTION>
                                                                                                      FROM
                                                                                                     MAY 31,
                                                                                                      2000
                                                                                                   (INCEPTION
                                                 THREE MONTHS ENDED        SIX MONTHS ENDED           DATE)
                                                     JANUARY 31,              JANUARY 31,           THROUGH
                                             -----------------------   ------------------------    JANUARY 31,
                                                2004         2003         2004          2003          2004
                                             ----------   ----------   ----------    ----------    ----------
                                                                         UNAUDITED
                                             -----------------------------------------------------------------
<S>                                            <C>         <C>         <C>          <C>            <C>
Operating expenses:

  Research and development                     312,561         --        849,076             --        849,076
  Cost related to warrants granted in
      consideration of research and
      license agreement                        836,249         --      6,311,919             --      6,311,919
  Marketing                                         --         --         15,340             --         15,340
  General and administrative                   115,220         --        319,985             --        319,985
  Cost related to warrants and shares
      granted to service providers                  --         --      3,533,750             --      3,533,750
                                           -----------    -------    -----------    -----------    -----------

                                             1,264,030         --     11,030,070             --     11,030,070
Financial expenses, net                            655         --            530             --            530
                                           -----------    -------    -----------    -----------    -----------

Net loss from continuing operations for
   the period                               (1,264,685)        --    (11,030,600)            --    (11,030,600)
Income (loss) from discontinued
   operations of a segment of a business            --    (12,043)        12,156        (15,199)       (92,668)
                                           -----------    -------    -----------    -----------    -----------


Net loss for the period                     (1,264,685)   (12,043)   (11,018,444)       (15,199)   (11,123,268)
                                           ===========    =======    ===========    ===========    ===========

Basic net loss per share from continuing         (0.07)                    (0.62)            --
                                           ===========    =======    ===========    ===========    ===========

Basic net loss per share from
   discontinued operations                          --    (0.0006)       (0.0007)     (0.0008)
                                           ===========    =======    ===========    ===========    ===========

Weighted average shares outstanding         18,036,000  18,036,000    18,036,000     18,036,000
                                           ===========    =======    ===========    ===========    ===========
</TABLE>


The  accompanying  notes  are an  integral  part of the  consolidated  financial
statements.

                                       4
<PAGE>


                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)
--------------------------------------------------------------------------------
IN U.S. DOLLARS

<TABLE>
<CAPTION>
                                                                                                TOTAL
                                                   ADDITIONAL     RECEIPTS                  SHAREHOLDERS'
                                       SHARE        PAID-IN      ON ACCOUNT   ACCUMULATED      EQUITY
                                      CAPITAL       CAPITAL      OF SHARES      DEFICIT     (DEFICIENCY)
                                    -----------   -----------   -----------   -----------   -------------
<S>                                       <C>       <C>           <C>          <C>               <C>
Balance as of May 31, 2000                   --            --            --            --             --

Stock issued for cash on May 31,
                             2000         1,504         8,496            --            --         10,000
Net loss for the period                      --            --            --        (4,784)        (4,784)
                                    -----------   -----------   -----------   -----------    -----------

Balance as of July 31, 2000               1,504         8,496            --        (4,784)         5,216

Stock issued for cash on July 17,
                             2001           300        39,700            --            --         40,000
Contribution of capital                      --        15,000            --            --         15,000
Net loss for the year                        --            --            --       (30,415)       (30,415)
                                    -----------   -----------   -----------   -----------    -----------

Balance as of July 31, 2001               1,804        63,196            --       (35,199)        29,801

Contribution of capital                      --        15,000            --            --         15,000
Net loss for the year                        --            --            --       (38,781)       (38,781)
                                    -----------   -----------   -----------   -----------    -----------

Balance as of July 31, 2002               1,804        78,196            --       (73,980)         6,020

Contribution of capital                      --        15,000            --            --         15,000
Net loss for the year                        --            --            --       (30,844)       (30,844)
                                    -----------   -----------   -----------   -----------    -----------

Balance as of July 31, 2003               1,804        93,196            --      (104,824)        (9,824)

Receipts on account of 1,535,164
  Common shares net of issuance
  expenses of $117,486                       --            --     1,801,470            --      1,801,470
Cost related to warrants granted
  in consideration of research
  and license agreement                      --     6,311,919            --            --      6,311,919
Expenses related to warrants and
  shares granted to service
  providers                                  --     3,533,750            --            --      3,533,750
Net loss for the period                      --            --            --   (11,018,444)   (11,018,444)
                                    -----------   -----------   -----------   -----------    -----------

Balance as of January 31, 2004            1,804     9,938,865     1,801,470   (11,123,268)       618,871
                                    ===========   ===========   ===========   ===========    ===========
</TABLE>



The  accompanying  notes  are an  integral  part of the  consolidated  financial
statements.

                                       5
<PAGE>


                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

CONSOLIDATED STATEMENTS OF CASH FLOWS
--------------------------------------------------------------------------------
IN U.S. DOLLARS


<TABLE>
<CAPTION>
                                                                                                         FROM
                                                                                                     MAY 31, 2000
                                                                              SIX MONTHS ENDED       (INCEPTION
                                                                                  JANUARY 31,        DATE) THROUGH
                                                                      -----------------------------    JANUARY 31,
                                                                           2004            2003          2004
                                                                      -------------   -------------- -------------
                                                                                        UNAUDITED
                                                                      --------------------------------------------

<S>                                                                    <C>            <C>           <C>
Cash flows from operating activities:

  Net loss                                                             (11,018,444)            --   (11,123,268)
  Adjustments required to reconcile net loss to net cash provided by
     (used in) operating activities:                                            --
  Cost related to warrants granted in consideration of research and
    license agreement                                                    6,311,919             --     6,311,919
  Expenses related to warrants and shares granted to services
    providers                                                            3,533,750             --     3,533,750
  Changes in operating assets and liabilities:
   Increase in prepaid expenses                                           (190,229)            --      (190,229)
   Increase in related parties - shareholders                                1,023             --         1,023
   Increase in accounts payable and accrued expenses                       163,850             --       163,850
   Increase in severance pay                                                 4,640             --         4,640
                                                                       -----------    -----------   -----------

Net cash used in continuing operating activities                        (1,193,491)            --    (1,298,315)
Net cash provided by (used in) discontinued operating activities           (12,677)           486        77,759
                                                                       -----------    -----------   -----------

Total net cash provided by (used in) operating activities               (1,206,168)           486    (1,220,556)
                                                                       -----------    -----------   -----------

Cash flows from investing activities:

  Net cash used in discontinued investing activities                            --             --       (15,000)
                                                                       -----------    -----------   -----------

Total net cash used in investing activities                                     --             --       (15,000)
                                                                       -----------    -----------   -----------

Cash flows from financing activities:

  Receipts on account of shares                                          1,801,470             --     1,801,470
                                                                       -----------    -----------   -----------

Net cash provided by continuing financing activities                     1,801,470             --     1,801,470
Net cash flows provided by discontinued financing activities                    --             --        34,741
                                                                       -----------    -----------   -----------

Total net cash provided by financing activities                          1,801,470             --     1,836,211
                                                                       -----------    -----------   -----------

Increase in cash and cash equivalents                                      595,302            486       600,655
Cash and cash equivalents at beginning of period                             5,353          6,787            --
                                                                       -----------    -----------   -----------

Cash and cash equivalents at end of period                                 600,655          7,273       600,655
                                                                       ===========    ===========   ===========

Non-cash financing activities:

Licenses purchased against notes payable                                        --             --        28,000
                                                                       ===========    ===========   ===========

Supplemental disclosures:

Interest paid                                                                   --            935         1,059
                                                                       ===========    ===========   ===========
</TABLE>


The  accompanying  notes  are an  integral  part of the  consolidated  financial
statements.

                                       6
<PAGE>


                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
IN U.S. DOLLARS

NOTE 1:-  GENERAL

          Tissera Inc. ("the  Company") was  incorporated  under the laws of the
          state of Washington on May 31, 2000.

          On  September  4,  2003,  the  former  president  of Bert  Logic  Inc.
          completed  a share  purchase  agreement  with the  Company's  existing
          shareholders,  who purchased 15,000,000 shares of the currently issued
          and  outstanding   18,036,000  of  the  Company's  Common  shares.  In
          connection with the consummation of the transaction,  the president of
          the Company  resigned as president  and sole  director of the Company.
          Pursuant to the agreement, the Company entered into an amended license
          agreement to sell Bit Error Rate Testers on a worldwide  non-exclusive
          basis. In exchange,  the Company obtained forgiveness of the remaining
          promissory note of $ 10,299, and accrued interest of $ 2,436. Also, in
          connection with the  transaction,  the former president of the Company
          agreed to forgive his shareholders' loan, in the amount of $ 2,442.

          Following the share purchase  agreement  dated  September 4, 2003, the
          management of the Company has decided to  discontinue  all  activities
          related to the sales of Bit Error Rate Testers, used for the integrity
          and reliability of  communication  channels.  The  discontinuation  of
          their  activity  was  accounted  for under the  provision of SFAS 144,
          "Accounting for the Impairment or Disposal of Long-Lived Assets".

          On October 8, 2003,  the Company  entered  into a research and license
          agreement with Yeda Research and Development Company Limited ("Yeda"),
          according  to  which  Yeda  provided  the  Company  with a  worldwide,
          exclusive  license to  develop,  manufacture  and sell  Yeda's  tissue
          transplant technologies (see also Note 3).

          On October 9, 2003,  the  Company's  Board of  Directors  resolved  to
          change the name of the  Company  from Bert Logic,  Inc.  to  "Tissera,
          Inc."

          On  October  27,  2003  the  Company   incorporated   a   wholly-owned
          subsidiary, Tissera Ltd.

          The  Company's  ability to continue  to operate as a going  concern is
          dependent on its ability to generate sufficient cash flows to meet its
          obligations on a timely basis, to obtain  additional  financing and to
          ultimately  attain  profitability.  The Company is  actively  pursuing
          financing through a private placement.  There is no assurance that the
          Company will raise sufficient capital and generate sufficient sales to
          enable the Company to continue its operations for the next 12 months.

          In the event the Company is unable to  successfully  raise capital and
          generate  revenues,   it  is  unlikely  that  the  Company  will  have
          sufficient cash flows and liquidity to finance its business operations
          as currently contemplated.  Accordingly, in the event new financing is
          not   obtained,   the   Company   will  likely   reduce   general  and
          administrative  expenses and delay  development  projects  until it is
          able to obtain sufficient financing.

          Management  is  actively   engaged  in  raising   capital  through  an
          additional  round of  financing,  and is  confident  of the ability to
          raise the  necessary  funds for the Company's  growth and  development
          activities.  There can be no assurance that  additional  funds will be
          available on terms acceptable to the Company, or at all.

                                       7
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

NOTE 2:-  SIGNIFICANT ACCOUNTING POLICIES

          The significant accounting policies followed in the preparation of the
          financial statements, on a consistent basis, are:

          a. The Company's fiscal year-end is July 31, 2003.

          b. Cash and cash equivalents:

             The Company considers all highly liquid instruments with a maturity
             of  three  months  or  less  at the  time  of  issuance  to be cash
             equivalents.

          c. Research and development costs:

             Research and development costs are charged to expenses as incurred.

          d. Severance pay:

             The  liability  of the  Company  for  severance  pay is  calculated
             pursuant to Israel's Severance Pay Law in Israel, based on the most
             recent salary of the employees multiplied by the number of years of
             employment  as of the  balance  sheet date and is  presented  on an
             undiscounted basis. The subsidiary's  employees are entitled to one
             month's  salary for each year of employment  or a portion  thereof.
             The  liability  for all of the  employees  is fully  provided by an
             accrual.

             Severance  expenses  for the six months  period  ended  January 31,
             2004, were $ 4,640.

          e. Comprehensive income:

             SFAS  No.  130,  "Reporting   Comprehensive  Income",   establishes
             standards  for the  reporting  and  presentation  of  comprehensive
             income  and  its  components  in the  financial  statements.  As at
             January  31,  2004,   the  Company  has  no  items  that  represent
             comprehensive income and, therefore, has not included a schedule of
             comprehensive income in the financial statements.

          f. Basic earnings (loss) per share:

             Basic earnings  (loss) per share have been calculated in conformity
             with  Financial   Accounting  Standards  Board  Statement  No.  128
             "Earnings  per  Share".   Basic  earnings   (loss)  per  share  are
             calculated  using the  weighted  average  number  of Common  shares
             outstanding  each  period.   The  Company  has  excluded  from  the
             calculation  of the  weighted  average  number of shares  1,535,164
             shares related to receipt on account of shares that shares were not
             issued as of the balance sheet date.

                                       8
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

NOTE 2:-  SIGNIFICANT ACCOUNTING POLICIES (CONT.)

          g. Use of estimates:

             The   preparation  of  financial   statements  in  conformity  with
             accounting  principles  generally  accepted  in the  United  States
             requires  management to make estimates and assumptions  that affect
             the reported  amounts of assets and  liabilities  and disclosure of
             contingent  assets  and  liabilities  at the date of the  financial
             statements and the reported amounts of revenues and expenses during
             the  reporting  period.  Actual  results  could  differ  from those
             estimates.

          h. Principles of consolidation:

             The consolidated  financial  statements include the accounts of the
             Company and its wholly-owned subsidiary.  Intercompany balances and
             transactions have been eliminated upon consolidation.

          i. Reclassification:

             Certain amounts from prior years have been  reclassified to conform
             to the current year  representation.  The  reclassification  had no
             effect on  previously  reported net loss,  shareholders  equity and
             cash flows.

          j. Recent accounting pronouncements:

             In June 2002,  FASB  issued  SFAS No.  146,  "Accounting  for Costs
             Associated  with Exit or Disposal  Activities".  The  provisions of
             this Statement are effective for exit or disposal  activities  that
             are  initiated  after  December  31, 2002,  with early  application
             encouraged.  This  Statement  addresses  financial  accounting  and
             reporting for costs associated with exit or disposal activities and
             nullifies  Emerging  Issues  Task  Force  (EITF)  Issue  No.  94-3,
             "Liability  Recognition for Certain Employee  Termination  Benefits
             and  Other  Costs  to Exit an  Activity  (including  Certain  Costs
             Incurred  in a  Restructuring)".  This  Statement  requires  that a
             liability for a cost associated  with an exit or disposal  activity
             be recognized  when the liability is incurred.  The Company adopted
             SFAS No. 146 on January 1,  2003.  The effect of  adoption  of this
             standard  on the  Company's  results of  operations  and  financial
             position is not expected to be material.

             FASB has also issued  SFAS No.  145,  147 and 149 but they will not
             have a material  effect on the  Company's  operations,  therefore a
             description  of each and their  respective  impact on the Company's
             operations have not been disclosed.

                                       9
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

NOTE 2:-  SIGNIFICANT ACCOUNTING POLICIES (CONT.)

             In December  2002,  the FASB issued SFAS No. 148,  "Accounting  for
             Stock-Based Compensation - Transition and Disclosure," which amends
             SFAS No. 123 to provide  alternative  methods of  transition  for a
             voluntary  change to the fair value based method of accounting  for
             stock-based  employee  compensation.  In  addition,  SFAS  No.  148
             expands the disclosure requirements of SFAS No. 123 to require more
             prominent   disclosures  in  both  annual  and  interim   financial
             statements about the method of accounting for stock-based  employee
             compensation and the effect of the method used on reported results.
             The transition  provisions of SFAS No. 148 are effective for fiscal
             years ended after December 15, 2002.  The disclosure  provisions of
             SFAS No. 148 are  effective for  financial  statements  for interim
             periods beginning after December 15, 2002. The Company adopted SFAS
             No. 148 on January 1, 2003. The effect of adoption of this Standard
             on the Company's  results of operations  and financial  position is
             not  material,  as the Company does not have a stock option plan in
             place.

             In May 2003, the FASB issued SFAS No. 150  ("Accounting for Certain
             Financing  Instruments with Characteristics of both Liabilities and
             Equity".  This Statement established standards for the issuer as to
             how to classify both  liabilities  and equity.  It requires that an
             issuer  will  classify a  financial  instrument  that is within its
             scope as a liability  (or an asset in some  circumstances)  because
             that  financial  instrument  embodies an  obligation of the issuer.
             This Statement is effective for financial  instruments entered into
             or modified  after May 31, 2003,  and otherwise is effective at the
             beginning  of the first  interim  period  beginning  after June 15,
             2003,  except for mandatory  redeemable  financial  instruments  of
             nonpublic  entities.  The Company does not expect that the adoption
             of this  standard  will have a  material  effect  on its  financial
             position or results of operations.

             In January 2003, the FASB issued FIN 46, "Consolidation of Variable
             Entities  "  ("FIN  46").  FIN  46  clarifies  the  application  of
             Accounting  Research  Bulletin  No.  51,  "Consolidated   Financial
             Statements"  to  those  entities  defined  as  "Variable   Interest
             Entities" (more commonly  referred to as special purpose  entities)
             in which  equity  investors  do not have the  characteristics  of a
             "controlling  financial  interest" or do not have sufficient equity
             at risk for the entity to finance its activities without additional
             subordinated  financial support from other parties.  FIN 46 applies
             immediately to all variable interest entities created after January
             31,  2003 and by the  beginning  of the  first  interim  or  annual
             reporting  period  commencing  after  March 15,  2004 for  variable
             interest  entities  created prior to February 1, 2003.  The Company
             does not except the adoption of FIN 46 to have a material impact on
             its results of operations or financial position.

          k. Interim financial statements:

             These interim unaudited financial  statements have been prepared on
             the same  basis as the  annual  financial  statements  and,  in the
             opinion of management,  reflect all adjustments, which include only
             normal  recurring  adjustments,  necessary  to  present  fairly the
             Company's financial position,  results of operations and cash flows
             for the periods  shown.  The results of operations for such periods
             are not necessarily  indicative of the results  expected for a full
             year or for any future period.

                                       10
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

NOTE 3:-  RESEARCH AGREEMENT

          On October 8, 2003,  the Company  entered  into a Research and License
          Agreement  (the  "Agreement")  with Yeda.  The  Company  conducts  the
          research  for a  period  of 3  years,  at the  Weizmann  Institute  of
          Science,   relates  to  an  invention   comprising  methods  of  organ
          transplantation  utilizing  developing  nephric  tissue.  The  License
          granted to the Company shall expire at the later of (i) the expiration
          of the patents in the country of sale,  or (ii) 15 years from the date
          of receipt of FDA New Drug  Approval  (in the United  States),  or the
          equivalent  in any other  country in which the products  are sold.  In
          addition, Yeda may terminate the agreement if the Company will fail to
          achieve certain  commercialization  and development  achievements,  as
          defined in the agreement.

          The Company  committed  to grant Yeda,  within 120 days of the date on
          which the  Agreement  is  signed,  (i) a  warrant,  exercisable  at an
          aggregate  exercise  price  of $ 900 to  purchase  up to  2.23% of the
          issued  and  outstanding  Common  shares  of the  Company  immediately
          following  the  exercise  of  such   warrant,   and  (ii)  a  warrant,
          exercisable  at an aggregate  exercise price of $ 1,100 to purchase up
          to  2.67%  of  the  issued  and  outstanding  shares  of  the  Company
          immediately following the exercise of such warrant,  provided that the
          maximum  number of Common  shares  that  Yeda may  exercise  under the
          warrants shall be 2,315,139 and 2,771,937  respectively  (in each case
          as such number of Common shares shall be appropriately adjusted in the
          event of  stock  splits,  stock  dividends,  capital  reorganizations,
          reclassifications, recapitalizations and the like as well as issuances
          or  sales  by  the  Company  of  shares  for  par  value  only,  for a
          consideration of less than par value and for no consideration,  all in
          accordance with the terms and conditions of said warrant,  which shall
          be satisfactory  to Yeda and to the Company).  Each such warrant shall
          be exercisable for a period beginning one year after the date on which
          the  Agreement  is  signed,  and  ending  at the later of (a) one year
          following the  termination of the Agreement and (b) 10 years after the
          date on which the  Agreement is signed.  As of the balance sheet date,
          the Company has not yet granted Yeda the warrants.

          The Company  also paid to Yeda the  following:  (i) with regard to the
          first year of the research period  (commencing on April 9, 2003),  the
          amount of $ 450,000 of which a non-refundable installment of $ 225,000
          was  due  October  9,  2003  and  was  paid  in  December  2003  and a
          non-refundable installment of $ 225,000 was due on January 9, 2004 and
          was paid in December 2003 (These  amounts are in addition to $ 450,000
          paid earlier, on account of the research for the first year); and (ii)
          with  regard to the second  and third  years of the  research  period,
          respectively, an amount which shall be not less than $ 900,000 and not
          more than $ 1,000,000 per year to be determined by mutual agreement of
          the  parties no later than 30 days  prior to the  commencement  of the
          relevant year, in four equal  quarterly  non-refundable  installments,
          payable in advance at the  beginning of each three month period during
          such year.  If the  parties  fail to reach  agreement  within the time
          frame  referred to above  regarding the amount of the research  budget
          payable  for the second or third year of the  research  period (as the
          case may be),  then  the  research  budget  for such  year  shall be $
          900,000 and Yeda shall  procure the  performance  of research for such
          reduced amount.

                                       11
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

NOTE 3:-  RESEARCH AGREEMENT (CONT.)

          The Company  undertakes to make its best effort to  commercialize  the
          licensed  products.  The Company also agreed to pay Yeda a license fee
          of (i) $ 50,000 per year, to be paid  commencing  the first year after
          the  completion  of research and  development  period;  (ii) 4% of net
          sales of all products using the licensed technology;  (iii) 33% of all
          sublicense  fees  for all  agreements  entered  into  within  one year
          following the Agreement  date, and (iv) 16% of all sublicense fees for
          all agreements entered into after such one year period.

NOTE 4:-  STOCK SPLIT

          The  Company's  Board of  Directors  resolved to  effectuate a forward
          split of the Company's Common shares on a 3:1 basis, which occurred on
          November 4, 2003. The additional shares issued pursuant to the forward
          stock split will be fully paid and non-assessable. All new shares will
          have the same par value, voting rights and other rights as old shares.
          The 3:1 forward stock split is being  effectuated  by  increasing  the
          number  of  issued  and  outstanding  shares  at  the  ratio  of  3:1.
          Accordingly,  as a result of the forward stock split,  the Company has
          18,036,000  shares  outstanding  and  81,964,000  authorized  unissued
          shares,  which shares may be issued in the future in  connection  with
          acquisitions,  subsequent financings or as determined by the Company's
          Board of  Directors.  All share and per share  data were  restated  to
          reflect the stock split effected November 4, 2003.

NOTE 5:-  SHASREHOLDERS' EQUITY

          a. The  Company  has granted  7,905,931  warrants  to purchase  Common
             shares  of  par  value  $0.0001,   and  shares,  at  no  additional
             consideration.  The  warrants  and shares  were  granted to service
             providers,  in exchange for research and  development  services and
             general  and  administrative  services.  Out of the total  warrants
             4,847,400  warrants  are fully vested and  non-forfeited  as of the
             commitment  date, and 381,531  warrants are vested over a period of
             three years.  The Company  accounted  for such  warrants  under the
             provision  of EITF  96-18,  and the  fair  value  of  warrants  was
             recorded  as  research  and  development  expenses  and general and
             administrative expenses at the commitment date.

          b. The  Company  has granted to certain  brokers  172,480  warrants to
             purchase  Common shares of par value $ 0.0001 at an exercise  price
             of $ 0.1. In addition, the Company granted to these brokers 397,440
             warrants  to  purchase  Common  shares  of par value $ 0.0001 at an
             exercise price at the range of $3.75 - $6.00. The fair value of the
             warrants was accounted for as issuance expense and was deducted for
             the Company's equity.

                                       12
<PAGE>

                                                                    TISSERA INC.
                                                     (FORMERLY: BERT LOGIC INC.)
                                                     A DEVELOPMENT STAGE COMPANY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

NOTE 6:-  SUBSEQUENT EVENTS

          Private placement:

          a. As of March 2004, the Company has sold 1,767,200 units at a price
             per unit of $1.25. Each unit consists of one share of common stock
             and three common stock purchase warrants. As of March 12, 2004,
             the Company raised gross proceeds in the amount of $2,209,000. In
             addition, the Company granted the investors 5,301,600 warrants
             with an exercise price in the range of $3.75 to $6.00. The
             warrants are exercisable within a period of six months to two
             years from the date of issuance. In connection with the sale of
             the units, the Company issued 397,400 warrants with an exercise
             price in the range of $3.75 to $6.00. The warrants are exercisable
             within a period of six months to two years from the date of
             issuance.

          b. Subsequent  to the balance  sheet date,  the Company has granted to
             certain employees  1,965,314  options to purchase  1,965,314 of the
             Company's  Common  shares at an exercise  price of $0.30 per share.
             The options are vested over a period of two years.

          c. On February 18, 2004,  the Company  granted to two of its Directors
             541,080 options to purchase  541,080 of the Company's Common shares
             at an exercise price of $1. The options are vested over a period of
             three years.

                                       13
<PAGE>



ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

Forward Looking Statements - Cautionary Statements
--------------------------------------------------

This Form 10-QSB contains certain "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended (the
"Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"). Specifically, all statements other than statements
of historical facts included in this report regarding Tissera, Inc.'s (the
"Company") financial position, business strategy and plans and objectives of the
Company's management for future operations are forward-looking statements. These
forward-looking statements are based on the beliefs of the Company's management,
as well as assumptions made by and information currently available to the
Company's management. When used in this report, the words "anticipate,"
"believe," "estimate," "expect," "intend," and words or phrases of similar
import, as they relate to the Company or Company management, are intended to
identify forward-looking statements. Such statements (the "cautionary
statements") reflect the current view of the Company's management with respect
to future events and are subject to risks, uncertainties, and assumptions
related to various factors including, without limitation, competitive factors,
general economic conditions, customer relations, relationships with vendors, the
interest rate environment, governmental regulation and supervision, seasonality,
product introductions and acceptance, technological change, changes in industry
practices, and one-time events. Although the Company believes that expectations
are reasonable, it can give no assurance that such expectations will prove to be
correct. Based upon changing conditions, should any one or more of these risks
or uncertainties materialize, or should any underlying assumptions prove
incorrect, actual results may vary materially from those described herein as
anticipated, believed, estimated, expected, or intended. All subsequent written
and oral forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by the applicable
cautionary statements. The Company does not assume any responsibility to
publicly update any of its forward-looking statements regardless whether factors
change as a result of new information, future events, or for any other reason.
The Company advises you to review any additional disclosures made in its 10-QSB,
8-K, and 10-KSB reports filed with the Commission.

Overview
--------

The Company was incorporated under the laws of the State of Washington on May
31, 2000. The Company develops, tests and intends to commercialize tissue
transplantation therapies based on an approach employing organ-specific
precursor tissues. The Company's future approach involves harvesting embryonic
mammalian tissue at the earliest stage at which stem cells commit to becoming
organ-specific precursor tissues and transplanting them in target human organ
systems. The technology of tissue transplantation was developed by Prof.
Reisner's lab at the Weizman Institute. The Company entered into a Research and
License Agreement with Yeda Research and Development Company Limited ("Yeda"),
which is located in Rehovot, Israel. Yeda is the technology transfer office of
the Weizman Institute of Science. The research is conducted in the Weizman
Institute under the supervision of Professor Yair Reisner of the Department of
Immunology. The Company holds a world-wide license that shall expire at the
later of (i) the expiration of the patents in the country of sale, or (ii) 15
years from the date of receipt of FDA New Drug Approval in the United States, or
the equivalent in any other country in which the products are sold.

                                       14
<PAGE>

Our principal offices are located at 17 Hata'asia street Or Yehuda 60212 Israel,
and our telephone number is +972-54-544-344 or (214) 668-1897. The Company was
formed under the laws of the state of Washington.

The Company is at development stage and, as a result, is devoting substantially
all of its efforts toward conducting research and development activities,
raising capital, pursuing regulatory approval, recruiting personal and building
its infrastructure. The Company has discontinued all activities related to the
activities of selling a bit error rate tester, used for the integrity and
reliability of communication channels.

Significant Transactions and Events
-----------------------------------

Change in Ownership and Amendment of License
--------------------------------------------

Effective September 4, 2003, Lance Rudelsheim, the Company's former officer,
director and majority shareholder, closed on a share purchase agreement with
certain buyers pursuant to which the buyers, purchased 15,000,000 shares of the
then outstanding 18,036,000 shares of common stock of the Company for an
aggregate purchase price paid to the individual Seller of $10,000. In connection
with the consummation of the transaction, Lance Rudelsheim resigned as President
and sole director of the Company and appointed Mr. Robert G. Pico as the new
sole director of the Company and as the Company's Chief Executive Officer. In
connection with the transaction, the Company amended its license agreement with
Reach Technologies, Inc. The parties agreed that, in exchange for the
forgiveness of the remaining promissory note of $10,299 and all accrued interest
(approximately but not limited to $2,400) owed by the Company to Reach, the
Company agreed to convert its license to sell bit error rate testers from an
exclusive license to a worldwide non-exclusive license.

On October 1, 2004, the Company nominated Dr. Vicki Rabenou, MD, as the Chief
Executive Officer of the Company and as a director and Chief Executive Officer
of Tissera Ltd, a wholly-owned subsidiary of the Company, located in Israel.
Further, on March 15, 2004, Dr. Rabenou was elected as a director of the
Company. Further, in December 2003, Meir Segev was appointed to the Board of
Directors.

Research Agreement
------------------

On October 8, 2003, the Company entered into a Research and License Agreement
(the "Research Agreement") with Yeda Research and Development Company Limited
located in Rehovot, Israel. The agreement relates to the rights of the Company
to license from Yeda the research conducted, and to be conducted, at the
Weizmann Institute of Science, under the supervision of Professor Yair Reisner
of the Department of Immunology, and relates to an invention comprising methods
of organ transplantation utilizing developing nephric tissue. The license
granted to the Company by Yeda shall expire at the later of the following:

         o    the expiration of the patents in the country of sale; or
         o    15 years from the date of receipt of FDA New Drug Approval (in the
              United States), or the equivalent in any other country in which
              the products are sold.

In consideration for entering into the Research Agreement, the Company has
issued Yeda:

                                       15
<PAGE>

         o    a warrant, exercisable at an aggregate exercise price of US $900,
              to purchase up to 2.23% of the issued and outstanding shares of
              common stock of the Company immediately following the exercise of
              such warrant; and
         o    a warrant, exercisable at an aggregate exercise price of US $1,100
              to purchase up to 2.67% of the issued and outstanding shares of
              the Company immediately following the exercise of such warrant.

However, the maximum number of shares of common stock that Yeda may exercise
under the warrants shall be 2,315,139 and 2,771,937, respectively (in each case
as such number of shares of common stock shall be appropriately adjusted in the
event of stock splits, stock dividends, capital reorganizations,
reclassifications, recapitalizations and the like as well as issuances or sales
by the Company of shares for par value only, for consideration less than par
value and for no consideration, all in accordance with the terms and conditions
of said warrant, which shall be satisfactory to Yeda and to the Company. Each
such warrant shall be exercisable for a period beginning one year after the date
of signature of the Research Agreement and ending at the later of the following:

         o    one year following the termination of the Research Agreement; and
         o    ten years after the date of signature of the Research Agreement
              and to have such further terms and conditions as shall be
              satisfactory to Yeda and the Company.

As further consideration, the Company also paid to Yeda the following:

         o    with regard to the first year of the research period (commencing
              on April 9, 2003), the amount of $450,000, of which a
              non-refundable installment of $225,000 was due and paid on October
              9, 2003 and a non-refundable installment of $225,000 was due and
              paid on January 9, 2004 (these amounts are in addition to $450,000
              paid earlier, on account of the research for the first year); and
         o    with regard to the second and third years of the research period,
              respectively, an amount which shall be not less than $900,000 and
              not more than $ 1,000,000 per year to be determined by mutual
              agreement of the parties no later than 30 days prior to the
              commencement of the relevant year, in four equal quarterly
              non-refundable installments, payable in advance at the beginning
              of each three month period during such year. If the parties fail
              to reach agreement within the time frame referred to above
              regarding the amount of the research budget payable for the second
              or third year of the research period (as the case may be), then
              the research budget for such year shall be $ 900,000 and Yeda
              shall procure the performance of research for such reduced amount.

The Company undertakes to make its best effort to commercialize the licensed
products. The Company also agreed to pay Yeda a license fee including the
following

         o    $50,000 per year, to be paid commencing the first year after the
              completion of research and development period;
         o    4% of net sales of all products using the licensed technology;
         o    33% of all sublicense fees for all agreements entered into within
              one year following the Agreement date, and
         o    16% of all sublicense fees for all agreements entered into after
              such one year period.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JANUARY 31, 2004 AS COMPARED TO
THE THREE MONTHS ENDED JANUARY 31, 2003

                                       16
<PAGE>

The Company has entered into a Research and License Agreement with Yeda Research
and Development Company Limited located in Rehovot, Israel. The Research
Agreement relates to the rights of us to have the license from Yeda related to
research conducted and to be conducted at the Weizmann Institute of Science,
under the supervision of Professor Yair Reisner of the Department of Immunology.
The Company will sponsor research in Prof. Reisner's laboratory for three years.
Prof. Reisner's team is continuing the research of applications employing kidney
precursor tissue. Prof. Reisner plans to begin experiments implanting kidney
precursor tissues harvested from human and pig embryos into pigs and monkeys.
This will allow scientists to monitor the growth of precursor tissues in a large
animal, to develop appropriate surgical techniques, to optimize the amount of
tissue transplanted and to determine the most suitable use of immunosuppressive
drugs. The Company will initially seek approval through pre-clinical development
in Israel and/or Europe. In order to satisfy our cash requirements for the next
12 months, including payments pursuant to our license agreement, we will need to
raise additional funds. In the next 12 months, we do not expect a significant
increase in the number of employees and we do not expect the purchase or sale of
significant plant or equipment.

Revenues and Costs of Goods Sold
--------------------------------

The Company is in its development stage therefore has no revenues and cost of
goods sold.

Operating expenses
------------------

Operating expenses for the quarter ended January 31, 2004 amounted to
$1,264,030. These expenses reflect the commencement of its development stage
operations. The research and development expenses amounted to $312,561. The most
significant research and development expense was related to research and
development activities performed by Yeda in the amount of $280,328. Expenses
related to the issuance of warrants granted in consideration of entering into
the Research Agreement amounted to $836,249, which was primarily attributable to
the warrant granted to Yeda. The Company had general and administrative expenses
totaling $115,220. The general and administrative expenses were attributed
mainly to the Company's legal expenses and directors and officers insurance. The
Company did not have operating expenses for the quarter ended January 31, 2003.

(Loss) from discontinued operations of a segment of a business
--------------------------------------------------------------

As a result of the discontinuance of its activities related to selling a bit
error rate tester, used for the integrity and reliability of communication
channels, the Company had a Loss of $12,043 in the quarter ending January 31,
2003. Such activity did not exist in the quarter ending January 31, 2004.

Net loss
--------

As a result of the above activities, the Company incurred a net loss of
$1,264,685 for the six months ending January 31, 2004, as compared to a net loss
of $12,043 for the period ending January 31, 2003.

Liquidity and capital resources
-------------------------------

The Company's cash and cash equivalents were $600,655 as of January 31, 2004,
compared to none as of January 31, 2003. This increase is attributed to funds
received on account of a private placement that the Company conducted (see note
6 of the financial statement). The Company had a working capital of $626,012 as
of January 31, 2004, compared to none as of January 31, 2003. The Company plans
to continue to finance its operations through a combination of private
placements of its securities,

                                       17
<PAGE>

stock issuances, debt issuances, mutual development with possible milestone
license payments and research and development programs. There are no assurances,
however, that the Company will be successful in obtaining an adequate level of
financing required for the long-term development and commercialization of its
planned products.

ITEM 3. CONTROLS AND PROCEDURES

(a)  Evaluation of disclosure controls and procedures.

     Our Chief Executive Officer and Chief Financial Officer (collectively the
     "Certifying Officers") maintain a system of disclosure controls and
     procedures that is designed to provide reasonable assurance that
     information, which is required to be disclosed, is accumulated and
     communicated to management timely. Under the supervision and with the
     participation of management, the Certifying Officers evaluated the
     effectiveness of the design and operation of our disclosure controls and
     procedures (as defined in Rule [13a-14(c)/15d-14(c)] under the Exchange
     Act) as of January 31, 2004. Based upon that evaluation, the Certifying
     Officers concluded that our disclosure controls and procedures are
     effective in timely alerting them to material information relative to our
     company required to be disclosed in our periodic filings with the SEC.

(b)  Changes in internal controls.

     Our Certifying Officers have indicated that there were no significant
     changes in our internal controls or other factors that could significantly
     affect such controls subsequent to the date of their evaluation, and there
     were no such control actions with regard to significant deficiencies and
     material weaknesses.

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. CHANGE IN SECURITIES

As of March 2004, the Company has sold 1,767,200 units at a price per unit of
$1.25. Each unit consists of one share of common stock and three common stock
purchase warrants. As of March 12, 2004, the Company raised gross proceeds in
the amount of $2,209,000. In addition, the Company granted the investors
5,301,600 warrants with an exercise price in the range of $3.75 to $6.00. The
warrants are exercisable within a period of six months to two years from the
date of issuance. In connection with the sale of the units, the Company issued
397,400 warrants with an exercise price in the range of $3.75 to $6.00. The
warrants are exercisable within a period of six months to two years from the
date of issuance.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

                                       18
<PAGE>

None.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a)   Exhibit     Description

      31.1        Certification of the Chief Executive Officer of Tissera, Inc.
                  pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

      31.2        Certification of the Chief Financial Officer of Tissera, Inc.
                  pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

      32.1        Certification of the Chief Executive Officer of Tissera, Inc.
                  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

      32.2        Certification of the Chief Financial Officer of Tissera, Inc.
                  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b)   Reports on Form 8-K

On November 5, 2003, the Company filed a Form 8-K reporting, under Item 5, the
amendment of the Research and License Agreement with Yeda research and
Development Company Limited and the forward split of its common stock.

On November 10, 2003, the Company filed a Form 8-K reporting, under Item 4, the
resignation of Manning Elliot, Chartered Accountants, at its independent
auditors.

On January 12, 2004, the Company filed a Form 8-K reporting, under Item 4, the
appointment of Ernst & Young LLP at its independent auditors.

                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
this Form 10-QSB Report, for the Quarter ended January 31, 2004 has been signed
below by the following person on behalf of the Registrant and in the capacity
and on the date indicated.


                  TISSERA, INC.

                  By:   /s/Vicki Rabenou
                        -----------------------
                        Vicki Rabenou
                        Chief Executive Officer


                  By:   /s/Alex Werber
                        -----------------------
                        Alex Werber
                        Chief Financial Officer




                                       19